Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biopharma M&A In An Era Of Elusive Growth, Capital Triage, and New Competitors

Executive Summary

Investor-friendly capital allocation and the rising strength of large biotechs and specialty pharmas have jeopardized Big Pharma’s position of strength in M&A. Analysis by Ernst & Young suggests that industry’s largest companies face unusual challenges – and must adapt to new marketplace realities.

Advertisement

Related Content

Capital Allocation In The Age Of Shareholder Activism
Licensing Deals Still Backloaded In 2013, But Biotechs Could Gain Leverage
Biopharma In 2013: A Rising Tide
The Post-Patent Cliff Tab: Pharma Battered But Still Financially Strong, Says Moody’s
Tax Benefits, Branded Portfolio, Synergies Drive Actavis’ Acquisition of Warner Chilcott
Ahead Of Schedule, Pfizer Prepares To Set Zoetis Free In Stock Swap
$7 Billion Amylin Buyout Boosts BMS, AZ Diabetes Partnership

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV004055

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel